Apollomics Inc - Ordinary Shares - Class A
APLM
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.84M
Close$
$6.16
70.6% downside
Current Fair Value
70.6% downsideOvervalued by 70.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.84 Million |
|---|---|
| Enterprise Value | $6.21 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.57 |
| Beta | 1.54 |
| Outstanding Shares | 421,000 |
Return
| Return on Equity | 928.20% |
|---|---|
| Return on Assets | -440.74% |
| Return on Invested Capital | -6517.78% |
Valuation & Multiples
| P/E Ratio | -2.84 |
|---|---|
| PEG | 2.42 |
| Price to Sales | 1.31 |
| Price to Book Ratio | -2.63 |
| Enterprise Value to Revenue | 0.9 |
| Enterprise Value to EBIT | -0.25 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | -0.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.54%▲ 2.40% |
|---|---|
| Total Invested | $223,769▲ 2326.73% |
| Investors Holding | 40% |
ESG Score
No data
About Apollomics Inc
3 employees
CEO: Hung-Wen Chen Apollomics, Inc. functions as a clinical-phase biotechnology enterprise, concentrating its efforts on discovering and advancing novel cancer treatments to meet crucial, underserved patient requirements. The company was co-founded by Lian...